Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Merck & Co., Inc. (NYSE: MRK) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. Merck is a New Jersey–incorporated biopharmaceutical preparation manufacturer whose common stock and multiple series of notes are registered on the New York Stock Exchange, as reflected in its Form 8-K filings.
Through this page, readers can review Merck’s current and historical filings, including Form 8-K reports on material events such as public offerings of long-dated notes under its automatic shelf registration statement on Form S-3ASR and announcements of restructuring programs. Filings related to quarterly and annual results, such as earnings releases furnished on Form 8-K, give additional context on the company’s financial condition and performance.
For a research-intensive company like Merck, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) are key sources for information on its human health and animal health businesses, major products like KEYTRUDA and GARDASIL, pipeline programs including WINREVAIR and Alzheimer’s disease candidates, risk factors and capital structure. Forms 3, 4 and 5, when filed, provide details on insider transactions by directors and officers.
Stock Titan enhances these filings with AI-generated explanations that highlight important sections, clarify technical language and point out items that may interest investors, such as new debt issuances, restructuring charges or significant acquisitions. Real-time updates from EDGAR help ensure that newly filed Merck documents, including 10-Ks, 10-Qs and Form 4 insider reports, appear promptly, allowing users to track regulatory disclosures related to MRK in a single, organized feed.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III received new equity awards. He was granted stock options for 5,045 shares of common stock at an exercise price of $113.15 per share and 2,298 restricted stock units, both vesting in three equal annual installments beginning 5/5/2027. Each restricted stock unit represents a contingent right to receive one Merck common share. After these awards, he directly holds 9,388.315 shares of Merck common stock.
Merck & Co., Inc. executive vice president Chirfi Guindo reported new equity awards and updated share holdings. He received a grant of 19,402 stock options with an exercise price of $113.15 per share, vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
He also received 6,628 restricted stock units, each representing one share of common stock, scheduled to vest and be distributed in three equal installments on the same dates. Following these awards, he holds 61,613.127 shares of common stock directly and 57.1377 shares indirectly through a 401(k) plan. These are compensation-related grants rather than open-market purchases or sales.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III reported routine equity compensation activity involving restricted stock units. On May 2, 2026, restricted stock units covering 383 shares of common stock were exercised and converted into common shares.
To cover tax obligations, 132 shares of common stock were disposed of in a tax-withholding transaction at $112.16 per share, a non‑market event. After these transactions, Smart directly held 9,388.315 shares of Merck common stock. The restricted stock units, each representing a contingent right to one Merck share, vest and are distributed in three equal installments on May 2 of 2024, 2025, and 2026.
Merck & Co., Inc. executive David R. Maraldo reported routine equity compensation activity involving restricted stock units that convert into common shares. On May 2, 2026, 552 restricted stock units vested and were exercised into 552 shares of common stock. To cover related tax obligations, 159 shares were disposed of in a tax-withholding transaction at $112.16 per share, a non-market sale handled by the company. Following these transactions, Maraldo directly holds about 18,212.434 Merck common shares. The vested restricted stock units are part of an award scheduled to vest in three equal installments on May 2 of 2024, 2025, and 2026.
Merck & Co., Inc. executive David R. Maraldo, EVP & President of Merck Manufacturing Division, filed an amended initial ownership report showing his current equity holdings. He reports 17,819.434 shares of Merck common stock held directly and 8,359.140 shares held indirectly through a 401(k) plan. The filing also lists multiple stock options on Merck common stock with exercise prices between $73.73 and $129.22 per share that expire between 2031 and 2035, plus several restricted stock unit awards scheduled to vest in equal installments from 2024 through 2028. The report reflects holdings only and does not show new purchases or sales.
Merck completed its tender offer for Terns Pharmaceuticals and effected a merger under Section 251(h) of the DGCL. Purchaser accepted 100,091,794 Shares tendered at $53.00 per Share, representing 86.36% of outstanding shares as of the Expiration Time (May 4, 2026), and closed the merger so that Terns became a wholly owned subsidiary. The Shares are expected to cease trading and be delisted from Nasdaq prior to the opening of business on May 5, 2026, and Parent intends to terminate registration under the Exchange Act.
Merck completed its tender offer for Terns Pharmaceuticals and effected a merger under Section 251(h) of the DGCL. Purchaser accepted 100,091,794 Shares tendered at $53.00 per Share, representing 86.36% of outstanding shares as of the Expiration Time (May 4, 2026), and closed the merger so that Terns became a wholly owned subsidiary. The Shares are expected to cease trading and be delisted from Nasdaq prior to the opening of business on May 5, 2026, and Parent intends to terminate registration under the Exchange Act.
Merck & Co., Inc. executive David R. Maraldo reports his equity holdings. He holds 17,819.434 shares of common stock directly and 8,359.140 shares through a 401(k) plan. He also holds multiple stock options covering 8,060 to 9,709 shares each, with exercise prices from $73.73 to $129.22, plus restricted stock units for 2,361, 581, and 552 shares that vest in scheduled installments.
Merck & Co., Inc. reported first‑quarter 2026 sales of $16.3 billion, up from $15.5 billion a year earlier, but swung to a net loss of $4.24 billion versus prior net income of $5.08 billion. Loss per diluted share was $(1.72) compared with earnings of $2.01.
The quarter was dominated by a $9.0 billion research and development expense from the asset acquisition of Cidara Therapeutics and higher overall R&D of $12.6 billion. Operating cash flow increased to $3.92 billion, while Merck used $8.78 billion of cash to acquire Cidara and ended the period with $5.33 billion in cash and cash equivalents.
Merck also agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, expects to record about $5.8 billion as an R&D charge at closing, and entered a $6.0 billion 364‑day term loan facility to help fund the deal. Ongoing 2024 and 2025 restructuring programs recorded $466 million of pretax charges in the quarter.
Merck & Co., Inc. EVP Chirfi Guindo reported routine equity compensation activity. On April 29, 2026, he exercised 1,967 restricted stock units, receiving the same number of Merck common shares. Of these, 969 shares were withheld to cover tax obligations.
After these transactions, Guindo held 61,613.127 Merck common shares directly, plus 57.1377 shares indirectly through a 401(k) plan, and 3,935 restricted stock units. The filing notes that restricted stock units vest and are distributed in three equal installments on April 29, 2026, 2027 and 2028, and holdings include shares from dividend reinvestment.
Merck & Co., Inc. executive vice president and president of MMD Sanat Chattopadhyay reported routine equity compensation activity. On April 29, 2026, he exercised 2,597 restricted stock units, converting them into the same number of Merck common shares. Of these, 1,130 shares were withheld to cover tax obligations, leaving a net increase in his directly held common stock. After these transactions, he directly owned 16,477 common shares and held additional indirect positions through three Grantor Retained Annuity Trusts, with 53,417, 57,622 and 74,289 common shares, respectively, over which he serves as sole trustee with complete investment control. He also continued to hold 5,194 restricted stock units that vest in three equal installments in 2026, 2027 and 2028.